PIPELINE

GARDP’s portfolio of antibiotic treatments

Since 2016, GARDP has developed a strong portfolio of antibiotics to treat drug-resistant infections and made progress through three core research and development programmes: children's antibiotics, sexually transmitted infections and serious bacterial infections.

Our children’s antibiotics projects are currently focused primarily on clinical development, including conducting the first ever studies designed to evaluate drugs such as flomoxef and fosfomycin as alternatives in the treatment of neonatal sepsis. Meanwhile, zoliflodacin—a potential new treatment for gonorrhoea in our sexually transmitted infections programme—is being investigated in a pivotal phase 3 trial.

Two antibiotics with the potential to treat infections caused by WHO priority pathogens are part of our serious bacterial infections programme: cefepime–taniborbactam, for which we are in the recruitment stage of a crucial phase 3 clinical trial; and cefiderocol, which was recently approved by the Federal Drugs Administration (FDA) and European Medicines Agency (EMA). Access work activities have already begun for all the projects mentioned above.